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  Bovine leukemia virus (BLV) envelope glycoprotein (gp51/ 
gp30T-), consisting of BLV gp51 and BLV gp30 that lacked 
its C-terminal transmembrane domain, was expressed in 
insect cells under the control of the baculovirus polyhedron 
promoter. Recombinant BLV gp51/gp30T- secreted from 
insect cells was determined by immunofluorescence, enzyme- 
linked  immunosorbent  and  western  blot  assays  using  a 
BLV-specific monoclonal antibody and BLV-positive bovine 
antibodies. An agar gel immunodiffusion (AGID) test using 
gp51/gp30T- as the antigen for the detection of BLV antibodies 
in serum was developed and compared to traditional AGID, 
which uses wild type BLV antigen derived from fetal lamb 
kidney cells. AGID with the recombinant BLV gp51/gp30T- 
was relatively more sensitive than traditional AGID. When 
the two methods were tested with bovine sera from the field, 
the recombinant BLV gp51/gp30T- and traditional antigen 
had a relative sensitivity of 69.8% and 67.4%, respectively, 
and a relative specificity of 93.3% and 92.3%. These results 
indicated  that  the  recombinant  BLV  gp51/gp30T-  is  an 
effective  alternative  antigen  for  the  diagnosis  of  BLV 
infection in cattle.
Keywords: AGID, baculovirus expression, bovine leukemia 
virus, glycoproteins
Introduction 
Bovine leukemia virus (BLV) is the viral agent of enzootic 
bovine leukemia (EBL) in cattle. With the exception of a 
few European countries, EBL is considered to have a 
worldwide distribution. Although the majority of infected 
cattle remain clinically asymptomatic, invisible losses in 
productivity have a significant economic impact on the 
dairy industry [4,24,26]. BLV is an oncogenic retrovirus of 
the Retroviridae family. Similar to other retroviruses, the 
envelope glycoprotein (Env) of BLV is the immunodominant 
protein in vivo [3,8,7,18]. The BLV env gene encodes a 
precursor protein that is processed into two subunits, gp51, 
the outer membrane subunit, and gp30, the transmembrane 
subunit, both of which are essential for viral infectivity [20, 
28]. A variety of diagnostic tests have been developed for 
BLV, including PCR-based assays, agar gel immunodiffusions 
(AGIDs), virus neutralization assays, and enzyme-linked 
immunosorbent assays (ELISAs) [1,9, 11,12,16,25]. The 
most widely used diagnostic methods for the serological 
detection of BLV-specific antibodies are AGID and ELISA, 
which are antigen-based assays that use either wild type 
BLV gp51 isolated from fetal lamb kidney (FLK) cells, or 
a recombinant BLV antigen that is expressed in insect cells 
[6,16,19,23]. Although the AGID test is less sensitive and 
specific than ELISA, AGID test has been widely used 
mainly for the routine diagnosis of serum samples because 
of the simplicity. However, the cell line FLK/BLV, used for 
antigen production of AGID, is known to be contaminated 
with bovine viral diarrhea virus (BVDV) [2,22]. Sometimes, 
cross-reactivity occurred between the BVDV antibodies 
induced by the vaccine and BVDV in the BLV antigen 
preparation. 
The aim of this paper is therefore to describe the production 
of gp51 and partial gp30 by recombinant baculovirus in 
insect cells. The recombinant protein was used for detection 
of antibodies in sera of BLV-infected cattle as AGID antigen. 
Materials and Methods
Cells and viruses
FLK cells chronically infected with BLV were cultured in 
Eagle’s minimum essential medium containing 10% fetal 
bovine serum. To obtain BLV antigen for traditional AGID, 
FLK cell culture supernatant was collected and concentrated 
according to the protocol of Miller and Van Der Maaten 
[16]. 
For the cloning and expression of recombinant BLV 
gp51/gp30T-, Sf-9 and Hi-five cells were cultured in SF 
900 II serum-free medium (Invitrogen, USA).332    Seong In Lim et al.
Fig. 1. Schematic illustrations of (A) the bovine leukemia virus 
(BLV) gp51/gp30T- expression vector (Korean isolate, Gene 
bank; AY 995174). The bold line represents the backbone of 
pBacPAK8, and restriction endonuclease sites are indicated. (B)
IFA of recombinant BLV gp51/gp30T- expressed in Hi-five cells
(left) and normal Hi-five cells (right). (C) Western blotting of 
recombinant BLV gp51/gp30T- with monoclonal antibody. Lane 
1: Control, Lane 2: Supernatant from recombinant BLV gp51 &
gp30T- baculovirus infected Hi-five cells. Molecular weight 
(kDa) is indicated.
Cloning and expression of BLV gp51/gp30T-
Recombinant BLV gp51/gp30T- (Korean isolate, Gene bank 
accession AY995174), which lacked the transmembrane 
region of gp30 and retained the signal peptide (amino acids 
1-409) was expressed. Genomic DNA was extracted from 
the blood of dairy cows that were naturally infected with 
BLV using a genomic DNA kit (Promega, USA). For the 
amplification of BLV gp51/gp30T- sequences, the following 
oligonucleotide primers were used: 5´-CTC GAG ATG 
CCC AAA GAA CGA CGG TC -3´, which contained a 
restriction enzyme site for Xho I at the 5´ end, and 5´-GCT 
GGA GAT CAC CGA GGC GGA -3´. The amplified DNA 
fragment was inserted into pGEM T-easy (Promega, USA) 
for sequencing. The cloned DNA fragment was then excised 
and ligated into the transfer vector pBacPAK8 (Clontech, 
USA), as shown in Fig. 1A. A translational stop codon was 
inserted downstream of BLV gp51/gp30T- at the Pac I 
restriction site (5´ TAATTA 3´) of pBacPAK8 BlvGP. 
Recombinant viruses were purified by plaque assay and 
screened for the expression of BLV gp51/gp30T- by 
immunofluorescence assay (IFA), BLV-ELISA (indirect- 
ELISA), and western blot using BLV-positive bovine serum 
and monoclonal antibody as previously described [13-15]. 
Detection of recombinant BLV gp51/gp30T-
Indirect (I)-ELISA was performed as previously described 
[15]. Briefly, 100 μL of the supernatant from Hi-five cells 
infected with recombinant baculovirus and non-infected 
control cells were diluted 1 : 10 (2 μg/mL) in 0.05 M 
carbonate-bicarbonate buffer (pH 9.6). And the 96-well 
microplates (Maxisorp; Nunc, USA) were coated with the 
diluted supernatant at 4
oC overnight. Plates were blocked 
with 10% skimmed milk (Marvel, UK) in phosphate buffered 
saline (PBS) at room temperature for 1 h. Subsequently, 
plates were washed 3 times with PBS containing 0.05% 
tween 20 (PBST) and incubated with a 1 : 25 dilution of test 
sera, including the reference positive serum (NVSL, USA) 
in 10% skim milk in PBST for 1 h at 37
oC. The plates were 
then washed 3 times with PBST. 100 μL of horseradish 
peroxidase labeled anti-bovine IgG (Pierce, USA) or each 
subclass (Serotec, UK), diluted 1 : 3,000 in PBST containing 
10% skimmed milk, were then added to each well and 
incubated for 1 h at 37
oC. 
The plates were washed 3 times with PBST and developed 
with commercially available 3, 3´, 5, 5´-tetramethyl-benzidine 
(Kirkegaard & Perry Laboratories, USA). After 30 min, 
the reaction was stopped by adding 100 μL of 0.5 M H2SO4. 
The optical density (OD) of the solution was measured at 
450 nm. The net OD of test well was calculated by the 
subtraction of OD from control well.
The recombinant BLV gp51/gp30T- was tested for its 
reactivity to an anti-gp51 MAb by western blotting. The 
anti-gp51 MAb were produced through the cell fusion 
method [29]. Briefly, the DNA fragment for BLV gp51/gp30T- 
was ligated with pSecTaq 2C DNA vector (Invitrogen, USA) 
and intramuscularly inoculated to Balb/c mice. Anti- BLV 
gp51/gp30T- MAbs were screened and selected by indirect 
ELISA. One hybridoma cell line was finally selected for 
Western blotting in this study.
Preparation of recombinant BLV gp51/gp30T- for 
AGID
For the production of recombinant BLV gp51/gp30T-, 
approximately 7.5 × 10
7 Hi-five cells were infected with 
the recombinant virus (AcBlvGP) at a multiplicity of 
infection of 0.1-1, and then cultured at 27
oC for 6 days. 
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30 min to remove cells, and then the supernatant was 
subjected to another round of centrifugation at 100,000 × g 
for 2 h. The supernatant was concentrated in a cellulose 
membrane (M.W. 12,000; GibcoBRL, USA) with polyethylene 
glycol (M.W. 8,000; Serva, Germany) for 12~18 h at room 
temperature. A fraction (1/100) of the initial supernatant 
volume was evaluated by AGID using the indicated 
reference sera. The concentration of recombinant antigen 
was determined using a BCA protein assay kit (Pierce, 
USA), according to the manufacturer’s instructions, and 
antigen was stored at 򰠏70
oC until use. AGIDs were 
conducted as previously described [5,16,17]. 
Identification of the BLV provirus 
For the detection of proviral DNA of BLV, DNA samples 
were prepared both from peripheral blood mononuclear 
cells (PBMCs) and whole blood by using commercially 
available DNA extraction Kit (Promega, USA). The first 
and nested PCR for proviral DNA of BLV was conducted 
according to the protocols described previously [1,17].
Animals and sera 
A dairy cow (Holstein) that was naturally infected with 
BLV in the field was obtained from a farm in Korea. The 
cow was fertilized naturally, and the calf was placed in 
conventional housing with the dam, and monitored for the 
presence of BLV-specific antibodies, as previously described 
[24,26,27]. Whole blood samples and sera were collected 
at 3-week intervals. 
The reference bovine sera (strong BLV-positive serum and 
negative serum) were purchased from National Veterinary 
Services Laboratories (USA). Two hundred and ten bovine 
serum samples that were collected at four slaughterhouses 
throughout Korea from 2003 to 2004 were also analyzed. 
The collected field sera were stored at 򰠏20
oC until use. 
Diagnostic AGID 
AGIDs were conducted according to the standard 
procedure recommended by the Office International des 
Epizooties [17]. Briefly, gel diffusion plates consisting of 
0.8% noble agar and 8.5% NaCl were allowed to stand at 
room temperature for 72 h before obtaining a reading. All 
test sera were initially screened by AGID using baculovirus- 
expressed BLV gp51/gp30T- and FLK-derived BLV antigen. 
Sera were also tested using a commercially available ELISA 
kit (IDEXX, USA). 
Data analysis
Calculations to determine test sensitivity and specificity 
were carried out as previously described [5]. Sensitivity 
and specificity were calculated according to the following 
equations:
% sensitivity = positive by both methods / (positive by 
both methods + positive by the standard 
and negative by the method being 
compared with the standard) × 100
% specificity = negative by both methods / (negative by 
both methods + negative by the standard 
and negative by the method being 
compared with the standard) × 100
Results
Expression of recombinant BLV gp51/gp30T-
DNA fragment for BLV gp51/gp30T- of BLV was amplified 
by PCR and the PCR product was inserted into the pGEM 
T-easy vector for sequencing. The nucleotide sequence of 
the amplified BLV gp51/gp30T- gene was compared with 
the previously published sequence (Gene bank accession 
AF503581) [28]. The sequence of BLV gp51/gp30T- showed 
95.5% nucleotide identity and 96.0% amino acid identity, 
respectively (data not presented here). The BLV gp51/gp30T- 
fragment was ligated with pBacPAK8 by using Xho I and 
Xba I restriction sites (Fig. 1A). After cotransfection with 
viral DNA and pBacPAK8 BLV gp51/gp30T- into Sf-9 
cells, recombinant clones were screened for the expression 
of BLV gp51/gp30T- by IFA and indirect-ELISA using 
positive bovine serum as indicated in Figs. 1B and 2. 
However, when the expressed cells and supernatant were 
compared at the same time by I-ELISA with positive 
bovine serum, the OD from the culture media was 10 times 
higher than the cells, showing that the expressed BLV 
gp51/gp30T- was secreted from the expressed cells (Fig. 
2A). In fact, a time course experiment indicated that the 
recombinant BLV gp51/gp30T- was secreted outside of the 
expressed cells in 24 h and retained up to 120 h post 
inoculation in the supernatant indicating that it would be 
possible to prepare the recombinant BLV gp51/gp30T- by 
simple purification methods as shown in Fig. 2B. In addition, 
it was possible to detect the expressed BLV gp51/gp30T-, 
with a molecular weight of 62 kDa, from the supernatant 
with anti-gp51 MAb by western blotting as expected (Fig. 
1C). 
BLV diagnosis using recombinant BLV gp51/gp30T- 
The AGID diagnostic potential was examined using 
recombinant BLV gp51/gp30T- as the antigen. The new 
antigen was serially diluted in duplicate and determined 
minimum concentration (data not present here). The 
minimum concentration was able to detect 0.3 mg/mL of 
BLV gp51/gp30T- (Fig. 2). The AGID results using 
recombinant BLV gp51/gp30T- were reproducible and 
consistent, and there were no significant variations in 
repeated tests. In the diagnostic AGIDs of a calf born to a 
BLV-infected mother, recombinant BLV gp51/gp30T 
yielded positive results at an earlier time point than the 
traditional antigen. The BLV antigen was detected the 
calf’s whole blood by PCR (Table 1). 334    Seong In Lim et al.
Fig. 2. Expression of recombinant BLV gp51/gp30T in expressed cells and supernatant. (A) Comparison of recombinant BLV 
gp51/gp30T- between expressed cells and supernatant by indirect enzyme-linked immunosorbent assay (I-ELISA) using reference 
positive (ST+) and negative (N) bovine sera. A: Hi-five cells only (infected), B: Supernatant from expressed cells, C: Control cells, D:
Supernatant (control). The results were expressed as optical density (OD) value at 5 days post inoculation (DPI). (B) Time course 
profiles of recombinant BLV gp51/gp30T- secretion from the expressed Hi-five cells by I-ELISA using reference positive bovine serum
(×25). The results were expressed as the OD value at 5 DPI.
Fig. 3. Agar gel immunodiffusion with recombinant BLV gp51/gp30T-
and fetal lamb kidney (FLK)-derived BLV antigen. The minimum
concentration was able to detect 0.3 mg/mL of this recombinant 
antigen. Ab, positive bovine reference serum (center well); F, 
FLK-derived BLV antigen (3 mg/mL); 1-3, recombinant BLV 
gp51 & gp30T-; (1) 0.5; (2) 0.38 and (3) 0.3 mg/mL, respectively.
Table 1. Diagnosis of bovine leukemia virus (BLV) using agar gel immunodiffusion (AGID) and PCR from a congenitally infected calf
Weeks after delivery
9 1 21 51 82 12 42 73 03 33 63 94 24 54 85 15 4
AGID
Antigen from BLV-infected FLK* cell 򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏+++
Recombinant gp51 & gp30T- protein 򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏+++++
Proviral
  DNA
First PCR 򰠏򰠏򰠏򰠏򰠏򰠏򰠏򰠏++++++++
Nested PCR 򰠏򰠏򰠏򰠏򰠏+++++++++++
*FLK: fetal lamb kidney.
Field analysis of BLV antibody detection by AGID 
A field evaluation of 210 serum samples was performed 
to determine the diagnostic efficiency of AGID using either 
recombinant baculovirus-expressed BLV gp51/gp30T- or 
traditional FLK-derived antigen. The same samples were 
analyzed using a commercially available diagnostic ELISA 
(IDEXX, USA). AGID using the recombinant BLV gp51/ 
gp30T- detected 31 positive samples from a total of 43 
positive sera (Table 2), whereas using the FLK-derived 
antigen detected 29 positive samples. The negative number 
for the recombinant is 179 (12 plus 167) and the negative 
number for the FLK is 181 (14 plus 167). 
The diagnostic efficiencies of traditional and recombinant 
antigen-based AGIDs were compared to a commercially 
available BLV-ELISA. AGID using recombinant BLV gp51/ 
gp30T- and traditional antigen had a relative sensitivity of 
69.8% and 67.4%, respectively, and a relative specificity of 
93.3% and 92.3% (Table 2). Overall, recombinant BLV 
gp51/gp30T- was more sensitive than the traditional FLK Immunodiffusion analysis using baculovirus-expressed recombinant BLV glycoprotein    335
Table 2. Comparison of different AGID antigens between BLV-infected (n = 43) and non-infected (n = 167) animals as previously 
determined by IDEXX ELISA Kits
FLK-derived antigen Recombinant gp51/gp30T- antigen
Positive Negative Positive Negative
Infection status
(IDXX ELISA)
BLV-infected (43)
BLV non-infected (167)
29
0
14
167
31
0
12
167
antigen in detecting BLV-positive sera. These results 
suggested that recombinant BLV antigen would be an 
effective tool for the sero-diagnosis of BLV.
Discussion
BLV gp51 and the BLV viral capsid protein (core protein, 
p24) are the immunodominant viral proteins in vivo. For 
this reason, the expression and purification of BLV gp51 
for use as an antigenic reagent represents a promising 
approach to the development of diagnostic assays, as well 
as vaccines [6,21]. BLV env encodes a single precursor 
protein cleaved into two subunits; the outer membrane 
protein, gp51, and the transmembrane subunit, gp30. BLV 
gp51 is the major envelope glycoprotein, whereas gp30 
contains an N-terminal fusion domain that participates in 
syncytium formation along with gp51, as well as a 
transmembrane domain [8,10,20,28]. In the current study, 
we have described the expression of recombinant gp51/ 
gp30T- using a baculovirus expression system, in which the 
C-terminal transmembrane domain of p30 is lacking, and 
the purification of BLV gp51/gp30T- for use as a diagnostic 
antigen. 
In contrast to BLV gp51, the BLV Env precursor protein 
is not secreted when it is expressed in insect cells [6,21]. In 
the current study, to eliminate the risk of antigen being 
retained in cells, we generated an env expression construct 
that encoded gp51 and the N-terminal region of gp30 
lacking the C-terminal cytoplasmic domain and we 
demonstrated that BLV gp51/gp30T- was secreted from 
insect cells. 
The FLK cell line is still the primary cell line used for 
BLV antigen production for commercial diagnostic tests. 
As this cell line is known to be contaminated with BVDV, 
the contamination may result in additional diagnostic 
problems concerning the specificity of the reactions [2,22].
Compared to the traditional production of BLV antigen 
derived from infected FLK cells, the current method is 
similar to previously described methods in that it is both 
simple and rapid [5]. Crude BLV gp51/gp30T- preparations 
were generated within a day from supernatants of spin- 
cultured insect cells, and provided sufficient antigen for 
more than 2,000 samples in a volume of 500 ml. There was 
no risk of adventurous viral contamination, as in the case 
with BVDV, and a low rate of variability from batch to 
batch might be achievable because of the simplicity in 
preparing AGID antigen. Furthermore, when we analyzed 
serum from a calf born to an infected mother, AGID with 
recombinant BLV gp51/gp30T- yielded positive results at 
an earlier time point than traditional AGID using FLK-BLV 
antigen. Recombinant BLV antigen proved to be more 
sensitive than the FLK/BLV antigen (by 2.4%). Overall, 
there was an increase in both in sensitivity and specificity 
in field tests of sera using recombinant BLV antigen, 
providing additional support for the use of recombinant 
BLV gp51/gp30T- as an alternative diagnostic antigen. 
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